Elion Therapeutics Initiates Phase 2 Trial of Turletricin for Invasive Mould Infections
Key Insights
Elion Therapeutics (search) has launched the TREAT-1 Phase 2 clinical trial evaluating turletricin (search) (EL219 (search)), a once-weekly, non-nephrotoxic polyene antifungal for early treatment of invasive mould infections.
The FDA has granted turletricin (search) both Qualified Infectious Disease Product (QIDP) and Fast Track designations, providing development incentives including priority review and five additional years of market exclusivity.
Turletricin (search) is engineered to selectively target fungal ergosterol rather than human cholesterol, potentially reducing kidney toxicity while maintaining broad-spectrum antifungal activity compared to amphotericin B.
Elion Therapeutics (search) announced the initiation of its Phase 2 clinical trial evaluating turletricin (search) (EL219 (search)) for early antifungal therapy in patients with suspected and confirmed invasive mould infection (search). The TREAT-1 study represents a significant milestone for the biotechnology company's lead candidate, which has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.
Novel Approach to Antifungal Treatment
Turletricin (search) is positioned as a next-generation derivative of amphotericin B (AmB), engineered to address the significant toxicity limitations of current polyene antifungals. Unlike AmB, which targets both human cholesterol and fungal ergosterol, turletricin demonstrates selectivity for fungal ergosterol, potentially mitigating renal toxicity while preserving broad-spectrum antifungal activity.
"The QIDP designation and initiation of the TREAT-1 study, with its novel design, represents a key milestone for turletricin (search) and underscores its distinctive potential as a once-weekly, broad-spectrum, non-nephrotoxic polyene antifungal used early in people with suspected IMI," said Dr. Kieren Marr, CEO of Elion Therapeutics (search).
TREAT-1 Trial Design and Objectives
The Phase 2 global TREAT-1 clinical trial is structured as a multicenter, randomized, double-blind study comparing turletricin (search) versus standard of care for early antifungal therapy in patients with suspected and confirmed invasive mould infection (search). The primary outcome measure focuses on all-cause mortality at Day 21 in the Intent-to-Treat (ITT) analysis set.
The study design reflects the critical importance of early intervention in invasive mould infections, which can cause severe or life-threatening illness in patients with compromised immune systems. Dr. Marr emphasized that "delayed antifungal therapy is associated with poor outcomes in those who lack adequate immune responses."
Regulatory Recognition and Market Potential
The FDA's QIDP and Fast Track designations underscore the significant unmet medical need in invasive fungal infection treatment. QIDP designation provides development incentives including priority review and eligibility for an additional five years of market exclusivity, recognizing turletricin (search)'s potential to address serious or life-threatening infections.
These designations are particularly significant given the limited treatment options available for invasive fungal infections (search). Currently, only four classes of antifungal drugs exist, and treatment is complicated by antifungal resistance, organ toxicities, and drug-drug interactions.
Addressing a Critical Medical Need
Invasive fungal infections (search) represent a substantial global health burden, with more than 150 million people suffering from serious fungal infections worldwide and approximately 2.5 million annual deaths resulting from severe, life-threatening fungal infections. These infections typically occur in individuals with compromised immune systems due to conditions including HIV/AIDS (search), cancer therapies, organ transplants, and severe lung disease.
The current standard of care relies heavily on amphotericin B, a highly efficacious natural product used since the 1950s. However, AmB's clinical utility is limited by severe toxicities including renal toxicity, electrolyte wasting, anemia, and inflammatory infusion reactions, as well as the requirement for daily intravenous infusion.
Clinical Development Progress
Phase 1 studies of turletricin (search) in healthy volunteers and patients with moderate and severe renal insufficiency have demonstrated favorable tolerability profiles with no adverse findings related to renal toxicity. The company is conducting additional Phase 2 clinical trials of turletricin in adult participants with suspected fungal infections and cryptococcal meningitis (search).
Elion Therapeutics (search) plans to present clinical data on turletricin (search) at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Munich, Germany. The presentation will highlight early clinical findings supporting turletricin's potential as a broad-spectrum, novel analog of amphotericin B designed to mitigate systemic toxicities.
Company Background and Funding
Elion Therapeutics (search), founded on the principle that mechanistic insights enable targeted optimizations of natural products, focuses on transforming the treatment of life-threatening fungal infections. In 2024, the company secured $82 million in Series B funding led by Deerfield Management (search) and the AMR Action Fund (search), with additional investment from Illinois Ventures (search).